Today: 20 May 2026
American Express stock (AXP) ends flat as Trump’s 10% credit-card cap keeps policy risk in play
15 January 2026
2 mins read

American Express stock (AXP) ends flat as Trump’s 10% credit-card cap keeps policy risk in play

New York, Jan 14, 2026, 21:06 EST — Market closed.

American Express shares ended Wednesday slightly higher, gaining 0.07% to close at $358.26. The stock steadied after a volatile start to the week for credit card companies. U.S. bank stocks remained under pressure as investors weighed President Donald Trump’s efforts to limit credit card interest rates.

The policy debate is crucial since American Express and other card issuers depend heavily on interest income and fees. A strict cap could squeeze their margins or alter how they underwrite loans. U.S. House Speaker Mike Johnson acknowledged Congress should consider the proposal but cautioned about “negative secondary effects” if lenders reduce credit access. Reuters

Investors are keeping an eye on the Credit Card Competition Act, which Senators Roger Marshall and Dick Durbin reintroduced this week. According to a statement from Marshall’s office, the bill would force large banks to support at least two unaffiliated card networks for credit-card transactions, including one beyond Visa and Mastercard. This targets the current “swipe fee” system, or interchange fees, that merchants pay on card purchases. Senator Roger Marshall

The sell-off has hit broadly. Visa shares dropped roughly 7% since Monday, American Express fell about 5%, and Mastercard slid close to 5%, Investopedia reports. William Blair analysts see the dip as a buying opportunity, urging long-term investors to “accumulate” these stocks despite current uncertainty. Citigroup’s team also noted that previous sell-offs sparked by worries over their business models have often rewarded those who stepped in. Investopedia

Markets are pricing in the headlines as a genuine near-term drag, despite widespread skepticism on Wall Street about the chances of swift approval. “Financials are getting hit by Trump’s credit-card proposal,” said Tim Ghriskey, senior portfolio strategist at Ingalls & Snyder, on Tuesday. He added that turning the proposal into reality would be “extremely difficult.” Reuters

A smaller competitor threw a curveball Wednesday. New York-based fintech Bilt announced a 10% introductory annual percentage rate (APR) for the first year on new cards. CEO Ankur Jain stated, “If (a credit card rate cap) is going to happen, we’d rather be at the forefront.” This move might ramp up political pressure on larger issuers like American Express. AP News

But the downside is clear. Citi CFO Mark Mason argued a 10% cap would block credit access for those who need it most and cause a “deleterious impact” on the economy. CEO Jane Fraser added that the damage to banks would be “dwarfed” by the blow to consumer spending if credit tightens. Business Insider

Thursday’s session will hinge on Washington. Traders will watch closely for any sign the administration can push a viable legislative plan, or if the proposal will remain just a headline that fades away. The longer uncertainty drags on, the more it could drag down valuations throughout the card complex.

American Express is set to release its fourth-quarter and full-year 2025 results on Jan. 30. The earnings materials will drop around 7 a.m. ET, followed by an 8:30 a.m. conference call. Investors will get a fresh update on spending patterns and credit costs, even as the policy debate continues in the background.

Stock Market Today

  • Roivant Sciences Q4 Loss Beats Estimates; Revenue Misses
    May 20, 2026, 9:59 AM EDT. Roivant Sciences Ltd. reported a fourth-quarter loss of $0.23 per share, better than the Zacks estimate of a $0.25 loss, marking an 8% positive earnings surprise. Revenue missed expectations, coming in at $28.93 million, down 11% from estimates but up from $27.38 million a year ago. Despite three out of four quarters beating EPS estimates recently, the company's shares have declined 4.5% year-to-date, underperforming the S&P 500's 10.4% rise. Earnings outlook remains cautious with a Zacks Rank #4 (Sell), suggesting expected near-term underperformance. Current consensus projects a loss of $0.21 per share next quarter on $56.64 million revenue and a fiscal year loss of $1.07 on $172.45 million. Industry outlook in medical-biomedical genetics also weighs on investor sentiment.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
EchoStar Corporation (SATS) stock jumps nearly 6% as Dish vendor dispute hits FCC SpaceX review
Previous Story

EchoStar Corporation (SATS) stock jumps nearly 6% as Dish vendor dispute hits FCC SpaceX review

Fortescue Ltd stock ends higher after Zitara deal — what FMG investors watch next week
Next Story

Fortescue Ltd stock ends higher after Zitara deal — what FMG investors watch next week

Go toTop